What question did this study set out to answer?

This research evaluates outcomes of donor lymphocyte infusion versus second transplant in allogeneic hematopoietic cell transplantation.

December 8, 2025BloodOpen Access

Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows donor lymphocyte infusion improves outcomes in myeloproliferative neoplasm post-relapse.

This research evaluates outcomes of donor lymphocyte infusion versus second transplant in allogeneic hematopoietic cell transplantation.
Retrospective analysis of 864 consecutive allo-HCTs in South Australia from 1990 to 2023
Assessments included overall survival, non-relapse mortality, and relapse using Kaplan–Meier and Cox regression
Comparison of post-relapse outcomes for patients receiving DLI versus allo-HCT2
Overall survival improved from 40.5% to 58.0% over 35 years due to reduced non-relapse mortality
Relapse risk has remained around 30% since 2000, indicating a persistent challenge for cure
Median OS was 15.5 months with DLI compared to 8.6 months with allo-HCT2 for relapsed patients

Cibich et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark